Mirum Pharmaceuticals Inc

F:08D

Business Description

Sector

Health Care

Industry

Biotechnology

Headquarters

United States of America US

Employees

369

IPO date

Jul 18, 2019

Mirum Pharmaceuticals makes prescription medicines for rare liver and metabolic diseases. Its main products are branded therapies for patients with serious genetic disorders, especially children and adults who live with cholestatic liver conditions and other uncommon diseases that have few treatment options. The company sells these medicines through the healthcare system, working with specialist doctors, hospitals, and specialty pharmacies.

Mirum makes money mainly by selling its approved drugs, not by selling devices or consumer products. Because these are prescription medicines for rare diseases, the customer is a small group of patients whose doctors need targeted treatments that are hard to find elsewhere. The company’s work also includes developing and expanding uses for its drugs in additional rare disease settings.

What makes Mirum different is its focus on a narrow set of hard-to-treat conditions where the whole business depends on deep clinical knowledge and close ties to specialist prescribers. Instead of aiming at large common diseases, it builds value around a small number of therapies that can become important standard treatments in their niche markets.